Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent?

Zu, Qing‐Quan; Schenning, Ryan C.; Jahangiri, Younes; Tomozawa, Yuki; Kolbeck, Kenneth J.; Kaufman, John A.; Al-Hakim, Ramsey; Naugler, Willscott E.; Nabavizadeh, Nima; Kardosh, Adel; Billingsley, Kevin G.; Mayo, Skye C.; Orloff, Susan L.; Enestvedt, C. Kristian; Maynard, Erin; Ahn, Joseph; Lhewa, Dekey; Farsad, Khashayar

doi:10.1007/s00270-020-02434-4

Cited by 6 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a large HCC tumor size (≥5 cm) was a factor of poor prognosis in some studies [46][47][48]. These studies included patients treated by glass microspheres, using the recommended method of activity planning (80-150 Gy to the targeted liver).…”

Section: Personalized Dosimetry In Sirtmentioning

confidence: 99%

Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria

et al. 2022

View full text Add to dashboard Cite

Selective internal radiation therapy (SIRT) is part of the treatment strategy for hepatocellular carcinoma (HCC). Strong clinical data demonstrated the effectiveness of this therapy in HCC with a significant improvement in patient outcomes. Recent studies demonstrated a strong correlation between the tumor response and the patient outcome when the tumor-absorbed dose was assessed by nuclear medicine imaging. Dosimetry plays a key role in predicting the clinical response and can be optimized using a personalized method of activity planning (multi-compartmental dosimetry). This paper reviews the main clinical results of SIRT in HCC and emphasizes the central role of dosimetry for improving it effectiveness. Moreover, some patient and tumor characteristics predict a worse outcome, and toxicity related to SIRT treatment of advanced HCC patient selection based on the performance status, liver function, tumor characteristics, and tumor targeting using technetium-99m macro-aggregated albumin scintigraphy can significantly improve the clinical performance of SIRT.

show abstract

Section: Personalized Dosimetry In Sirtmentioning

confidence: 99%

Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria

et al. 2022

View full text Add to dashboard Cite

show abstract

“…From the perspective of transarterial therapy, the small (30-60 micron) particles used in radioembolization are less likely to pose ischemic risks in the setting of portal venous invasion with advanced HCC (26). With external beam radiotherapy, the concept of treatment tolerability and ability to target suitable radiation fields with portal venous invasion is of interest (6,27).…”

Section: Role Of Xrt For Hccmentioning

confidence: 99%

Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure

et al. 2020

Self Cite

View full text Add to dashboard Cite

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study

Shen,

Zhang,

Liu

et al. 2024

JHC

View full text Add to dashboard Cite

Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent?

Cited by 6 publications

References 28 publications

Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria

Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria

Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study

Contact Info

Product

Resources

About